The AST/ALT (De Ritis) ratio predicts clinical outcome in pancreatic cancer patients treated with first-line nab-paclitaxel and gemcitabine: post-hoc analysis of an Austrian multicenter, non-interventional study

Authors :: Gerald W. Prager
E. Hubmann
S. Thamer
Sonja Burgstaller
Friedrich Längle
Johannes Andel
Jakob M. Riedl
Wolfgang Eisterer
M. Pecherstorfer
P. Pichler
Ewald Wöll
Leopold Öhler
K. Wilthoner
Kathrin Philipp-Abbrederis
Birgit Gruenberger
M. Korger
A. Petzer
Richard Greil
Florian Posch
Thomas Winder
Angela Djanani
Armin Gerger
Source :: Annals of Oncology. 30:iv78
Publication Year :: 2019
Publisher :: Elsevier BV, 2019.

Subjects :: Oncology
medicine.medical_specialty
business.industry
First line
Hematology
medicine.disease
Gemcitabine
Pancreatic cancer
Internal medicine
Post-hoc analysis
Non interventional
medicine
business
Nab-paclitaxel
medicine.drug

Full Text Access

Tools